Vivek Ramaswamy

I know what you're talking about. Okay. And this... pisses me the hell off because I know how cynical the intentions are of just deceiving and straight up lying to people about it. And at some point- But about what? Yeah, so I'll lay out for you. So like there's this false allegation that somehow there was an Alzheimer's trial that I made a bunch of money off of that failed. It's bullshit.

But here's actually the reality. So I think it's essentially more important than that. There's a lot in my own business background that informs my worldview and what we're trying to do for the country. So I started a biotech company. It was my first company, major company that I started back in 2014. Okay. I've been an investor. I worked at a hedge fund in New York.

But here's actually the reality. So I think it's essentially more important than that. There's a lot in my own business background that informs my worldview and what we're trying to do for the country. So I started a biotech company. It was my first company, major company that I started back in 2014. Okay. I've been an investor. I worked at a hedge fund in New York.

But here's actually the reality. So I think it's essentially more important than that. There's a lot in my own business background that informs my worldview and what we're trying to do for the country. So I started a biotech company. It was my first company, major company that I started back in 2014. Okay. I've been an investor. I worked at a hedge fund in New York.

And it turned out pharma companies are among the more inefficient companies when it comes to allocating their money to developing drugs. A bunch of pharma companies tend to get out of a therapeutic area at the exact same time. So when they throw in their towel, they all kind of follow the fad and go in a new direction. And there's a lot of reasons why.

And it turned out pharma companies are among the more inefficient companies when it comes to allocating their money to developing drugs. A bunch of pharma companies tend to get out of a therapeutic area at the exact same time. So when they throw in their towel, they all kind of follow the fad and go in a new direction. And there's a lot of reasons why.

And it turned out pharma companies are among the more inefficient companies when it comes to allocating their money to developing drugs. A bunch of pharma companies tend to get out of a therapeutic area at the exact same time. So when they throw in their towel, they all kind of follow the fad and go in a new direction. And there's a lot of reasons why.

But they all kind of throw the towel in the same areas at the same time that go from being in favor to out of favor. Hmm. So my premise was to start a biotech company that took a lot of the projects that they had discarded after spending a lot of money on them. Find the ones that they discarded, not necessarily because they were bad drugs. Oh, because it wasn't a trend.

But they all kind of throw the towel in the same areas at the same time that go from being in favor to out of favor. Hmm. So my premise was to start a biotech company that took a lot of the projects that they had discarded after spending a lot of money on them. Find the ones that they discarded, not necessarily because they were bad drugs. Oh, because it wasn't a trend.

But they all kind of throw the towel in the same areas at the same time that go from being in favor to out of favor. Hmm. So my premise was to start a biotech company that took a lot of the projects that they had discarded after spending a lot of money on them. Find the ones that they discarded, not necessarily because they were bad drugs. Oh, because it wasn't a trend.

Yeah, because it was a trend and they had capital allocation issues that they had to allocate in a new direction. And see if you could make one of those drugs work. Exactly. And so some of these areas were women's health and urology. Alzheimer's was one of these areas for sure, where 99.7% of drugs ever tested for Alzheimer's disease had failed.

Yeah, because it was a trend and they had capital allocation issues that they had to allocate in a new direction. And see if you could make one of those drugs work. Exactly. And so some of these areas were women's health and urology. Alzheimer's was one of these areas for sure, where 99.7% of drugs ever tested for Alzheimer's disease had failed.

Yeah, because it was a trend and they had capital allocation issues that they had to allocate in a new direction. And see if you could make one of those drugs work. Exactly. And so some of these areas were women's health and urology. Alzheimer's was one of these areas for sure, where 99.7% of drugs ever tested for Alzheimer's disease had failed.

A bunch of these companies are just like throwing the towel. So I set up a company called Roivant. And the whole model was, A, you give skin in the game to the scientists who actually develop these drugs. They don't get that at big pharma. And B, focus on the areas where pharma had abandoned them. A subset of these are going to work. Not all of them are going to work.

A bunch of these companies are just like throwing the towel. So I set up a company called Roivant. And the whole model was, A, you give skin in the game to the scientists who actually develop these drugs. They don't get that at big pharma. And B, focus on the areas where pharma had abandoned them. A subset of these are going to work. Not all of them are going to work.

A bunch of these companies are just like throwing the towel. So I set up a company called Roivant. And the whole model was, A, you give skin in the game to the scientists who actually develop these drugs. They don't get that at big pharma. And B, focus on the areas where pharma had abandoned them. A subset of these are going to work. Not all of them are going to work.

Biotech is a game of, it's a numbers game. Yeah. But enough are going to work to be able to create a successful company. And I was convinced of that based on what I had seen. So I started the company. We developed a number of drugs in these subsidiaries. So each of those units, one was focused on Alzheimer's. One was focused on women's health. One was focused on dermatology and so forth.

Biotech is a game of, it's a numbers game. Yeah. But enough are going to work to be able to create a successful company. And I was convinced of that based on what I had seen. So I started the company. We developed a number of drugs in these subsidiaries. So each of those units, one was focused on Alzheimer's. One was focused on women's health. One was focused on dermatology and so forth.

Biotech is a game of, it's a numbers game. Yeah. But enough are going to work to be able to create a successful company. And I was convinced of that based on what I had seen. So I started the company. We developed a number of drugs in these subsidiaries. So each of those units, one was focused on Alzheimer's. One was focused on women's health. One was focused on dermatology and so forth.

And the way I made my money was that five of those drugs that we developed through phase three and successful phase three studies went on to become FDA approved. And the one I'm probably most proud of is a drug actually for the smallest of those markets.